Cellbricks Therapeutics

Transformative tissue therapeutics. Repair tissue defects and restore organ function.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Berlin, Germany
  • Currency EUR
  • Founded August 2016
  • Employees 23
  • Incorporation Type Other
  • Website cellbricks.com

Company Summary

Cellbricks Therapeutics pioneers the future of regenerative medicine and longevity. Our mission is to transform healthcare by replacing damaged tissue and restoring organ function with living, cell-based implants - produced at scale using our proprietary 3D-bioprinting platform. Following strong pre-clinical results, approval for first-in-human trials is planned for 2027.

Review pitch deck for details:
https://docsend.com/v/32vcp/gust

Team

  • CO-CEO (Business) & Co-founder

    Formerly founded & exited deep-tech start-up to Hexagon.
    12 years building and leading teams in start-up and corporate settings

  • CO-CEO (Therapeutic Programs)

    Former CEO at RegenHU and BioAscent ; CBO at Axol Bioscience; Director at Kyorin Pharmaceutical Co. 25 years building and  leading biotech, pharma and regenerative medicine, across US, EU, Asia

  • Chief Medical Officer (CMO)

    Former Head of Rare Diseases, Immunology, J&J; Exec. Dir., Novartis; Pediatric gastro-hepatologist & clinical pharmacologist, UCLA & USC. 20 years combined experience in clinic & drug development, driving innovative therapies to new markets

  • Michael Kring, MBA
    CFO

    Owner of High Tech Corporate Services, former Group CFO at BioNTech SE.
    20 years experience in financial modelling and controlling.

  • Dr. Tobias Lam
    CTO & Co-founder

    Creator of Cellbricks’ bioprinting technology. 10 years experience of 3D-bioprinting, biomaterial formulation and 3D-Bioprinter development

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free